ABL’s Bispecific Antibody For Parkinson's Lands In Sanofi’s Hands

$1bn Deal A CNS Leg Up For French Firm?

ABL Bio’s $1.06bn license deal with Sanofi for Parkinson's antibody is seen offering favorable terms to Korean biotech and is also poised to beef up French group’s presence in the space versus competitors.

partnership
Hefty Upfront, Near Term Milestones For ABL Bio • Source: Alamy

ABL Bio Inc. has reached an exclusive worldwide license agreement with Sanofi to develop and commercialize the South Korean biotech’s still preclinical stage, enhanced blood-brain barrier (BBB) penetration bispecific antibody ABL301 for Parkinson’s disease and other potential indications, in a deal worth up to $1.06bn.

"This ground-breaking partnership with Sanofi proves the immense possibilities of ABL's innovative bispecific antibody technology," declared ABL CEO Sang Hoon...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.